Reuters logo
BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia
October 12, 2017 / 7:18 AM / 2 months ago

BRIEF-Karyopharm and Ono Pharmaceutical sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

Oct 12 (Reuters) - Karyopharm Therapeutics Inc

* Karyopharm and Ono Pharmaceutical Co. Ltd. sign exclusive license agreement to develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia

* Says ‍under terms Karyopharm will receive a one-time upfront payment of yen 2.5 billion from Ono​

* Co eligible to receive up to an additional about $170.7 million if specified future development and commercial milestones are achieved by Ono​

* Ono will receive exclusive rights to develop and commercialize both compounds in territory, at its own cost and expense​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below